Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty

Description

This study will examine the efficacy of Liposomal Bupivacaine (Exparel) in hip fracture patients undergoing hip hemiarthroplasty for femoral neck fractures through a posterior approach. Post-operative measures will be assessing pain, overall opiate use, delirium, time-to-ambulation and discharge status.

Study Start Date

March, 01 2018

Estimated Completion Date

July 2019

Interventions

  • Drug: Bupivacaine liposome
  • Drug: Saline

Study ID

Maimonides Medical Center -- 2016-10-01

Status

Unknown

Trial ID

NCT03502018

Study Type

Interventional

Trial Phase

Phase 4

Enrollment Quota

50

Sponsor

Maimonides Medical Center

Inclusion Criteria

    Men and women sixty-five years of age and older with isolated intracapsular hip fractures undergoing hemi arthroplasty through a posterior approach with the ability to consent to the study.

Exclusion Criteria

    Under sixty-five years of age, extracapsular hip fracture, suffer from any form of cognitive compromise that leaves them unable to consent, or if they are treated with any surgical modality other than hip hemiarthroplasty.

Gender

All

Ages

65 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Maimonides Medical Center - Brooklyn, New York 56.3 miles Daniel Komlos MD PhD 718-283-8805 dkomlos@maimonidesmed.org

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.